Liver involvement in inflammatory bowel disease: What should the clinician know?
Giuseppe Losurdo,Irene Vita Brescia,Chiara Lillo,Martino Mezzapesa,Michele Barone,Mariabeatrice Principi,Enzo Ierardi,Alfredo Di Leo,Maria Rendina +8 more
13
About: This article is published in World Journal of Hepatology. The article was published on 27 Nov 2021. and is currently open access. The article focuses on the topics: Inflammatory bowel disease.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The preventive effect of Glycyrrhiza polysaccharide on lipopolysaccharide-induced acute colitis in mice by modulating gut microbial communities.
TL;DR: In this article , the authors investigated whether GPS attenuated the upregulation of tumour necrosis factor-α, interleukin (IL)-1β, and IL-6 in the serum and colon tissues and significantly reduced the malondialdehyde content in colon tissues.
25
Association of Serum Malondialdehyde Levels with Lipid Profile and Liver Function in Patients with Inflammatory Bowel Disease
Nayra Merino de Paz,Marta Carrillo‐Palau,Alejandro Hernández-Camba,Pedro Abreu‐Gonzalez,Antonia de Vera-González,Alejandra González‐Delgado,Candelaria Martín‐González,Miguel Á. González‐Gay,Iván Ferraz‐Amaro +8 more
TL;DR: This cross-sectional study of 197 IBD patients found significant associations between serum malondialdehyde (MDA) levels and lipid profile abnormalities, liver fibrosis, and hepatic elastography values, but not with disease activity or demographic characteristics.
3
Predictive Factors of Surgical Recurrence in Patients with Crohn’s Disease on Long-Term Follow-Up: A Focus on Histology
Gian Paolo Caviglia,Chiara Angela Mineo,Chiara Rosso,Angelo Armandi,Marco Astegiano,Gabriella Canavese,A. Resegotti,Giorgio Maria Saracco,Davide Giuseppe Ribaldone +8 more
TL;DR: The heterogeneous spectrum of factors associated to the risk of surgical recurrence in patients with CD that underwent ileocolic resection supports the need of a personalized follow-up taking into account different clinical, surgical, and histologic features.
Si-Ni-San alleviates intestinal and liver damage in ulcerative colitis mice by regulating cholesterol metabolism
Anhui Wang,Xue Yang,Jia-Chun Lin,Yali Wang,Jinni Yang,Yuting Zhang,Yuan Tian,Haijuan Dong,Zunjian Zhang,Rongrong Song +9 more
TL;DR: Si-Ni-San, a traditional Chinese medicinal formula, alleviates intestinal and liver damage in ulcerative colitis mice by regulating cholesterol metabolism, providing a potential therapeutic approach for inflammatory bowel diseases through unclear bioactive mechanisms.
1
References
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents☆
Alfredo Papa,Carla Felice,Manuela Marzo,Gianluca Andrisani,Alessandro Armuzzi,Marcello Covino,Giammarco Mocci,Daniela Pugliese,Italo De Vitis,Antonio Gasbarrini,Gian Lodovico Rapaccini,Luisa Guidi +11 more
TL;DR: HBV and HCV infection rates were similar to infection rates among the general population, and anti-TNF-α agents appear to be safe for patients with HBV infection; more data are needed for Patients withHCV infection.
Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
Ayesha Shah,Graeme A. Macdonald,Graeme A. Macdonald,Graeme A. Macdonald,Mark Morrison,Gerald Holtmann,Gerald Holtmann,Gerald Holtmann +7 more
TL;DR: A bidirectional interplay of the gut-liver axis with critical roles for the gastrointestinal microbiome and circulating bile acids (BAs) in the pathophysiology of PSC is suggested.
62
Update on inflammatory bowel disease in patients with primary sclerosing cholangitis
TL;DR: The aim of this literature review was to shed light to the obscure clinical and molecular aspects of the two diseases combined utilizing current data available and putting issues of diagnosis and treatment into perspective.
New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease
Edward Shelton,K. Chaudrey,Jenny Sauk,Hamed Khalili,Ricard Masia,Deanna Nguyen,Vijay Yajnik,Ashwin N. Ananthakrishnan +7 more
TL;DR: There is minimal data on this occurrence in inflammatory bowel disease (IBD) patients, but anti‐tumour necrosis factor α (anti‐TNF) agents have been implicated in drug‐induced liver injury.
59
Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease
TL;DR: IBD patients with NAFLD had longer disease duration of IBD and developed NA FLD with fewer metabolic risk factors than patients withNAFLD only, suggesting that there may be other factors that contribute to the development of NAFLd in the IBD population.